Vascular endothelial growth factor (VEGF) plays an important role in the growth and metastasis of non-small-cell lung cancer (NSCLC). The aim of this study was to develop an RNA-interference approach that targets VEGF, using a recombinant plasmid, and to explore its antitumor efficacy in NSCLC in vivo. shRNA-targeting VEGF was cloned into pGenesil-2 plasmid vector and then transfected into A549 human lung cancer cells, using cationic liposome. Reverse-transcriptase polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) analysis were used to evaluate the silencing effects of VEGF-shRNA on A549 cells in vitro. Further, the growth-inhibition capacity of VEGF-shRNA on A549 lung carcinoma xenografts was tested in nude mice. Proliferation, apoptosis, and angiogenesis in tumor tissues were measured by PCNA, TUNEL, and CD31 immunohistochemistry, respectively. shRNA-targeting VEGF significantly silenced VEGF expression in A549 lung cancer cells, as confirmed by RT-PCR and ELISA assay (P < 0.01). In vivo, the VEGF-shRNA delayed tumor growth and reduced tumor weight by ∼61.96%, compared with control groups (P < 0.05), accompanied with angiogenesis inhibition (P < 0.01) and apoptosis induction (P < 0.01). Our data showed that the knockdown of VEGF by shRNA might be a potential therapeutic approach against human NSCLC.
Get full access to this article
View all access options for this article.
References
1.
ParkinDM, BrayF, FerlayJet al.Global cancer statistics, 2002. CA Cancer J Clin, 2005; 55:74.
2.
NovelloS, Le ChevalierT. Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park), 2003; 17:357.
3.
FolkmanJ. Role of angiogenesis in tumor growth and meta-stasis. Semin Oncol, 2002; 29,6 Suppl 16:15.
4.
RobinsonCJ, StringerSE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci, 2001; 114,Pt 5:853.
5.
GabrilovichD, IshidaT, OyamaTet al.Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 1998; 92:4150.
6.
PidgeonGP, BarrMP, HarmeyJHet al.Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer, 2001; 85:273.
KayaA, CiledagA, GulbayBEet al.The prognostic significance of vascular endothelial growth factor levels in sera of non-small-cell lung cancer patients. Respir Med, 2004; 98:632.
10.
YuanA, YuCJ, ChenWJet al.Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Int J Cancer, 2000; 89:475.
11.
ShimanukiY, TakahashiK, CuiRet al.Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small-cell lung cancer. Lung, 2005; 183:29.
OkaN, SoedaA, InagakiAet al.VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun, 2007; 360:553.
17.
DuXB, LangJY, XuJRet al.Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis. Apoptosis, 2008; 13:1205.
18.
SchillerJH, HarringtonD, BelaniCPet al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. NE JM, 2002; 346:92.
19.
RabenD, HelfrichB, BunnPAJr.Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys, 2004; 59,2 Suppl:27.
20.
CristofanilliM, CharnsangavejC, HortobagyiGN. Angiogenesis modulation in cancer research: Novel clinical approaches. Nat Rev Drug Discov, 2002; 1:415.
21.
BachelderRE, CragoA, ChungJet al.Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res, 2001; 61:5736.
22.
JacksonMW, RobertsJS, HeckfordSEet al.A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res, 2002; 62:854.
23.
TianX, SongS, WuJet al.Vascular endothelial growth factor: Acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun, 2001; 286:505.
24.
GiacconeG. The potential of antiangiogenic therapy in non-small-cell lung cancer. Clin Cancer Res, 2007; 13:1961.
25.
PrestaLG, ChenH, O'ConnorSJet al.Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res, 1997; 57:4593.
26.
ShaheenRM, DavisDW, LiuWet al.Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res, 1999; 59:5412.
27.
HolashJ, DavisS, PapadopoulosNet al.VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A, 2002; 99:11393.
28.
GoldmanCK, KendallRL, CabreraGet al.Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A, 1998; 95:8795.
29.
CaoY. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol, 2001; 33:357.
30.
FerraraN. VEGF as a therapeutic target in cancer. Oncology, 2005; 69,Suppl 3:11.
31.
KongHL, CrystalRG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst, 1998; 90:273.
32.
NabelGJ, NabelEG, YangZ-Yet al.Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. PNAS, 1993; 90:11307.
33.
GuanH, ZhouZ, WangHet al.A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res, 2005; 11:2662.
34.
MulkeenAL, SilvaT, YooPSet al.Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: Effects on cellular proliferation in colon cancer cells. Arch Surg, 2006; 141:367discussion, 374.
35.
GuoY, GuoH, ZhangLet al.Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells. J Virolo, 2005; 79:14392.
36.
ZhdanovRI, PodobedOV, VlassovVV. Cationic liposome-DNA complexes-lipoplexes for gene transfer and therapy. Bioelectrochemistry, 2002; 58:53.
37.
YoungLS, MautnerV. The promise and potential hazards of adenovirus gene therapy. Gut, 2001; 48:733.
38.
JiaoX, WangRY, QiuQet al.Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by codelivery of protein antigen and CpG with cationic liposomes. J Gen Virol, 2004; 85,Pt 6:1545.
39.
ZelphatiO, SzokaFCJr.Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci U S A, 1996; 93:11493.
40.
SangareL, MorissetR, OmriAet al.Incorporation rates, stabilities, cytotoxicities, and release of liposomal tetracycline and doxycycline in human serum. J Antimicrob Chemother, 1998; 42:831.
41.
WebbMS, HarasymTO, MasinDet al.Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer, 1995; 72:896.
42.
YuanF, DellianM, FukumuraDet al.Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res, 1995; 55:3752.
43.
SimbergD, WeismanS, TalmonYet al.DOTAP (and other cationic liposomes): Chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst, 2004; 21:257.
44.
TousignantJD, GatesAL, IngramLAet al.Comprehensive analysis of the acute toxicities induced by systemic administration of cationic liposome:plasmid DNA complexes in mice. Hum Gene Ther, 2000; 11:2493.
